FLAGYL ER (metronidazole) by Pfizer is mechanism of action metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. First approved in 1997.
Drug data last refreshed 11h ago
Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on FLAGYL ER at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo